Is mitochondrial oxidative metabolism the right therapy target in early Huntington disease?

@article{Lodi2017IsMO,
  title={Is mitochondrial oxidative metabolism the right therapy target in early Huntington disease?},
  author={Raffaele Lodi},
  journal={Neurology},
  year={2017},
  volume={88},
  pages={116 - 117}
}
  • R. Lodi
  • Published 10 January 2017
  • Biology, Medicine
  • Neurology
Huntington disease (HD) is a progressive and fatal autosomal dominant neurodegenerative disorder characterized by extrapyramidal motor signs often preceded by cognitive and behavioral disturbances, with a prevalence of 5–10 cases per 100,000 people worldwide1; expanded CAG repeats within the coding sequence of the HTT gene on chromosome 4p2 are the cause. The gene encodes huntingtin (HTT), a ubiquitously expressed protein associated with most intracellular organelles. CAG repeats of 40 or more… 
View on Publisher
neurology.org

References

SHOWING 1-10 OF 10 REFERENCES
Molecular mechanisms and potential therapeutical targets in Huntington's disease.
TLDR
The data that describe the emergence of the ancient huntingtin gene and of the polyglutamine trait during the last 800 million years of evolution are reviewed and data indicating how the loss of these beneficial activities reduces the ability of these neurons to survive are summarized.
Energy metabolism defects in Huntington's disease and effects of coenzyme Q10
TLDR
Evidence for a generalized energy defect in Huntington's disease is provided, and a possible therapy is suggested to treat patients with coenzyme Q10.
Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease
TLDR
It was found that oral administration of either coenzyme Q10 or remacemide significantly extended survival and delayed the development of motor deficits, weight loss, cerebral atrophy, and neuronal intranuclear inclusions in the R6/2 transgenic mouse model of HD.
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
Huntington's disease
TLDR
Your contributions to the investigation of this tragic disorder are presented and a review of current ideas about the disease is reviewed.
Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy
TLDR
The findings show that HD and DRPLA share a deficit of in vivo mitochondrial oxidative metabolism, supporting a role for mitochondrial dysfunction as a factor involved in the pathogenesis of these polyglutamine repeat–mediated neurodegenerative disorders.
Striatal and white matter predictors of estimated diagnosis for Huntington disease
HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia
TLDR
The data are consistent with the hypothesis that different HTT haplotypes have different mutation rates, and geographic differences in HTT Haplogroups explain the difference in HD prevalence, and suggest that CAG-tract size is not the only factor important for CAG instability.
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
TLDR
These data do not justify use of CoQ as a treatment to slow functional decline in HD, and Class I evidence that CoQ does not slow the progressive functional decline of patients with HD is provided.
Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects.
TLDR
Oral administration of coenzyme Q10 markedly attenuated striatal lesions produced by systemic administration of 3-nitropropionic acid and significantly increased life span in a transgenic mouse model of familial amyotrophic lateral sclerosis, providing further evidence that coen enzyme Q10 can exert neuroprotective effects that might be useful in the treatment of neurodegenerative diseases.